PLOD1 and type 2 diabetes mellitus: The data obtained significantly change the strategy for the possible use of complex therapy with MF (and, possibly, other antidiabetic drugs) and LH/hCG-R-agonists (and, possibly, other activators of steroidogenesis) to compensate for impaired steroidogenesis and spermatogenesis in T2DM and indicate the need for further research in this areas, including clinical.